Positive clinical data may drive near-term interest in IRD shares. Key catalyst is BEST1 Cohort 1 data in September 2026. Monitor for further enrollment and safety updates.
Price Chart
Executive Summary
Opus Genetics reported positive clinical data for its LCA5 gene therapy (OPGx-LCA5) showing over 30-fold improvement in cone sensitivity and visual acuity gains in pediatric patients. Early BEST1 data also showed improved visual acuity and retinal structure in adults. The results support broad pipeline potential and regulatory readiness.
Key Facts
- OPGx-LCA5: >30-fold improvement in cone sensitivity, visual acuity gains, well-tolerated in pediatric LCA5 patients at 6 months.
- OPGx-BEST1: up to 12-letter visual acuity improvement, ~23% reduction in central subfield thickness in first adult participant at 3 months.
- Preclinical RHO data show durable retinal preservation and support mutation-independent approach.
- BEST1 Cohort 1 topline data expected September 2026.
Financial Impact
No revenue or earnings impact; early-stage clinical data. Positive readthrough for pipeline value but pre-commercial.
Risk Factors
- Early-stage data; larger trials needed to confirm efficacy and safety.
- Regulatory and manufacturing risks for gene therapies.
- Potential dilution from future capital raises.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3290656 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | SC 13G | $3.32 | awaiting T+60 | — | $3.46 (+4.22%) |
Oct 27, 2026 today | Insider Cluster | $3.32 | awaiting T+60 | — | $3.46 (+4.22%) |
Oct 23, 2026 4d ago | 144 | $3.32 | awaiting T+60 | — | $3.46 (+4.22%) |
Oct 21, 2026 6d ago | 8-K | $3.82 | awaiting T+60 | — | $3.46 (−9.42%) |
Oct 15, 2026 12d ago | 8-K | $3.84 | awaiting T+60 | — | $3.46 (−9.90%) |
Oct 15, 2026 12d ago | Press Release | $3.84 | awaiting T+60 | — | $3.46 (−9.90%) |
Sep 22, 2026 5w ago | Institutional Cluster | $5.16 | awaiting T+60 | — | $3.46 (−32.95%) |
Sep 11, 2026 6w ago | 8-K | $6.04 | awaiting T+60 | — | $3.46 (−42.72%) |
Sep 9, 2026 6w ago | 8-K | $5.73 | awaiting T+60 | — | $3.46 (−39.62%) |
Sep 2, 2026 7w ago | Press Release | $4.45 | awaiting T+60 | — | $3.46 (−22.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers